At a glance
- Originator Bristol-Myers Squibb
- Class Antihyperlipidaemics; Bisphosphonates
- Mechanism of Action Squalene synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 10 Aug 1998 No-Development-Reported for Atherosclerosis in USA (Unknown route)
- 28 Apr 1995 New profile
- 28 Apr 1995 Preclinical development for Atherosclerosis in USA (Unknown route)